Translational Research in Genitourinary Oncology
Lines of Research
02.Development of new antineoplastic molecules in genitourinary tumours
03.Prognostic and predictive biomarkers in genitourinary cancer
04.Advanced therapies in uro-oncology
- Research projects
- Clinical studies
- Scientific Publications
- Technological Offers
- Industrial property records
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Ensayo aleatorizado en fase IIIb para comparar la irradiación más la supresión adyuvante de andrógenos a largo plazo con antagonista de la GnRH frente al agonista de la GnRH más prevención de los brotes en pacientes con riesgo muy alto de cáncer de próstata localizado o localmente avanzado. Estudio conjunto ROG y GUCG de la EORTC. Pegasus
ANA MARÍA OTERO ROMERO – ENSAYO CLINICO INDEPENDIENTE – EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER
An open-label, randomized study to assess the relative bioavailability (BA) and bioequivalence (BE) of fixed-dose Estudio abierto, aleatorizado para evaluar la biodisponibilidad (BD) relativa y la bioequivalencia (BE) en formulaciones de combinación a dosis fija (CDF) de niraparib y acetato de abiraterona (AA) comparado con niraparib y AA co-administrado como único agente en hombres con cáncer de próstata
– ENSAYO CLINICO COMERCIAL – JANSSEN-CILAG INTERNATIONAL N.V.
“Patrones de tratamiento y seguimiento prolongado de los pacientes con cáncer de próstata que recibieron darolutamida en el ensayo ARAMIS – PARASEC”
JUAN ANDRES CANTERO MELLADO – ESTUDIO OBSERVACIONAL CON MEDICAMENTO – BAYER HISPANIA S.L.
“Estudio observacional, multinacional y prospectivo de resultados clínicos en pacientes con cáncer de próstata hormonosensible metastásico (CPHSm) tratados con ADT más apalutamida o enzalutamida en la práctica clínica habitual (Estudio ArtemisPRO).
DAVID HERNANDEZ ALCARAZ – ESTUDIO OBSERVACIONAL CON MEDICAMENTO – JANSSEN-CILAG INTERNATIONAL N.V.
A PROSPECTIVE RANDOMISED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY WITH OR WITHOUT LOCAL RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-NAÏVE PROSTATE CANCER
RAQUEL CORREA GENEROSO – ENSAYO CLINICO INDEPENDIENTE – GCS UNICANCER R&D (NO USAR)
Importance of dose in palliative treatment for incurable head and neck cancer with radiotherapy
Garcia-Anaya, MJ; Ordonez, R; Toledo, MD; Correa, RC; Otero, A; Roman, A; Garcia-Rios, I; Medina, JA; Gomez-Millan, J – 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Lozano, R; Lorente, D; Aragon, IM; Romero-Laorden, N; Nombela, P; Mateo, J; Reid, AHM; Cendon, Y; Bianchini, D; Llacer, C; Sandhu, SK; Sharp, A; Rescigno, P; Garces, T; Pacheco, MI; Flohr, P; Massard, C; Lopez-Casas, PP; Castro, E; de Bono, JS; Olmos, D – 2021
Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study.
Martin-Bravo, C; Quiros, R; Blancas, I; Villatoro-Roldan, R; Robles, M; Alcaide, J; Navarro, V; Perez, D; Zarcos, I; Rivas-Ruiz, F; Perez-Ruiz, E; Quero, C – 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Sweeney, C; Bracarda, S; Sternberg, CN; Chi, KN; Olmos, D; Sandhu, S; Massard, C; Matsubara, N; Alekseev, B; Parnis, F; Atduev, V; Buchschacher, GL; Gafanov, R; Corrales, L; Borre, M; Stroyakovskiy, D; Alves, GV; Bournakis, E; Puente, J; Harle-Yge, ML; Gallo, J; Chen, G; Hanover, J; Wongchenko, MJ; Garcia, J; de Bono, JS – 2021
Apalutamide and Overall Survival in Prostate Cancer
Smith, MR; Saad, F; Chowdhury, S; Oudard, S; Hadaschik, BA; Graff, JN; Olmos, D; Mainwaring, PN; Lee, JY; Uemura, H; De Porre, P; Smith, AA; Brookman-May, SD; Li, S; Zhang, K; Rooney, B; Lopez-Gitlitz, A; Small, EJ – 2021
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
Cattrini, C; Espana, R; Mennitto, A; Bersanelli, M; Castro, E; Olmos, D; Lorente, D; Gennari, A – 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer
Lozano, R; Salles, DC; Sandhu, S; Aragon, IM; Thorne, H; Lopez-Campos, F; Rubio-Briones, J; Gutierrez-Pecharroman, AM; Maldonado, L; di Domenico, T; Sanz, A; Prieto, JD; Garcia, I; Pacheco, MI; Garces, T; Llacer, C; Romero-Laorden, N; Zambrana, F; Lopez-Casas, PP; Lorente, D; Mateo, J; Pritchard, CC; Antonarakis, ES; Olmos, D; Lotan, TL; Castro, E – 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
Conteduca, V; Wetterskog, D; Castro, E; Scarpi, E; Romero-Laorden, N; Gurioli, G; Jayaram, A; Lolli, C; Schepisi, G; Wingate, A; Casadei, C; Lozano, R; Brighi, N; Aragon, IM; Marin-Aguilera, M; Gonzalez-Billalabeitia, E; Mellado, B; Olmos, D; Attard, G; De Giorgi, U – 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
Feng, FLY; Thomas, S; Saad, F; Gormley, M; Yu, MK; Ricci, DS; Rooney, B; Brookman-May, S; McCarthy, S; Olmos, D; Chowdhury, S; Hadaschik, B; Liu, Y; Davicioni, E; Smith, MR; Small, EJ – 2021
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer
Lorente, D; Llacer, C; Lozano, R; de Velasco, G; Romero-Laorden, N; Rodrigo, M; Sanchez-Iglesias, A; di Capua, C; Castro, E; Ferrer, C; Sanchez-Hernandez, A; Olmos, D – 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
Aldea, M; Lam, L; Orillard, E; Perez, CL; Saint-Ghislain, M; Gravis, G; Flechon, A; Roubaud, G; Barthelemy, P; Ricci, F; Priou, F; Neviere, Z; Beaufils, M; Laguerre, B; Hardy, AC; Helissey, C; Ratta, R; Borchiellini, D; Pobel, C; Joly, F; Castro, E; Thiery-Vuillemin, A; Baciarello, G; Fizazi, K – 2021
Relationships of Gut Microbiota Composition, Short-Chain Fatty Acids and Polyamines with the Pathological Response to Neoadjuvant Radiochemotherapy in Colorectal Cancer Patients.
Sanchez-Alcoholado, L; Laborda-Illanes, A; Otero, A; Ordonez, R; Gonzalez-Gonzalez, A; Plaza-Andrades, I; Ramos-Molina, B; Gomez-Millan, J; Queipo-Ortuno, MI – 2021
DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review
Armstrong, N; Quek, RGW; Ryder, S; Ross, J; Forbes, C; Fox, KM; Castro, E – 2021
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
Oliva, L; Lozano, R; Llacer, C; Aragon, I; Pajares, BI; Saez, MI; Herrera-Imbroda, B; Montesa, A; Hernandez, D; Villatoro, R; Otero, A; Correa, R; Grau, G; Peinado, P; Pacheco, MI; Garcia-Galisteo, E; Rueda, A; Machuca, FJ; Alba, E; Marquez-Aragones, A; Olmos, D; Castro, E – 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations
Sokolova, AO; Marshall, CH; Lozano, R; Gulati, R; Ledet, EM; De Sarkar, N; Grivas, P; Higano, CS; Montgomery, B; Nelson, PS; Olmos, D; Sokolov, V; Schweizer, MT; Yezefski, TA; Yu, EY; Paller, CJ; Sartor, O; Castro, E; Antonarakis, ES; Cheng, HTH – 2021
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
del Alba, AG; Mendez-Vidal, MJ; Vazquez, S; Castro, E; Climent, MA; Gallardo, E; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Arranz, JA – 2021
GABAergic deficits in absence of LPA(1) receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus.
Rosell-Valle, C; Martinez-Losa, M; Matas-Rico, E; Castilla-Ortega, E; Zambrana-Infantes, E; Gomez-Conde, AI; Sanchez-Salido, L; de Guevara-Miranda, DL; Pedraza, C; Serrano-Castro, PJ; Chun, J; de Fonseca, FR; Alvarez-Dolado, M; Santin, LJ; Estivill-Torrus, G – 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1) an-label, 2 trial
de Bono, JS; Mehra, N; Scagliotti, GV; Castro, E; Dorff, T; Stirling, A; Stenzl, A; Fleming, MT; Higano, CS; Saad, F; Buttigliero, C; van Oort, IM; Laird, AD; Mata, M; Chen, HC; Healy, CG; Czibere, A; Fizazi, K – 2021
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
Lozano, R; Castro, E; Aragon, IM; Cendon, Y; Cattrini, C; Lopez-Casas, PP; Olmos, D – 2021
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment
de Porras, VR; Wang, XC; Palomero, L; Marin-Aguilera, M; Sole-Blanch, C; Indacochea, A; Jimenez, N; Bystrup, S; Bakht, M; Conteduca, V; Piulats, JM; Buisan, O; Suarez, JF; Pardo, JC; Castro, E; Olmos, D; Beltran, H; Mellado, B; Martinez-Balibrea, E; Font, A; Aytes, A – 2021
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Members
-
Researcher in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
Bernardo Herrera Imbroda
-
Co-investigator in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
Elisa Matas Rico
Email: Elisa.matas@ibima.eu
ORCID
SCOPUS
-
Collaborating Healthcare ResearcherSerá Investigador Asistencial Colaborador el Investigador que no reúne la consideración de Investigador Posdoctoral. Estarán adscritos a un Grupo de Investigación liderado por un IR. Las funciones serán las que le tenga asignada su IR.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Postdoctoral and/or junior researchersEsta etapa posdoctoral estará restringida a Investigadores del Instituto que tengan el título doctor y no contemplados en los perfiles posteriores. Durante su etapa posdoctoral pueden llegar a liderar proyectos de I+D+i como Investigadores Principales, aunque aún no hayan establecido un nivel significativo de independencia. Además, pueden tener actividades de docencia y/o asistencial más allá de su trabajo de investigación.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Technical staff
Los investigadores predoctorales y/o en formación serán aquellos investigadores que realizan investigaciones bajo supervisión en una línea de investigación orientada a la resolución de problemas de salud. Incluye aquellos investigadores que están cursando un doctorado (incluyendo a los contratados Río Hortega)
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.